Published in Hepatology on April 01, 1991
Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg (1994) 4.24
Baboon-to-human liver transplantation. Lancet (1993) 4.01
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg (2001) 1.73
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology (1991) 1.21
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Persistence of extrahepatic hepatitis B virus DNA in the absence of detectable hepatic replication in patients with baboon liver transplants. J Med Virol (1995) 1.03
Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg (1999) 1.01
Liver transplantation. Gut Liver (2009) 0.93
Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A (1993) 0.91
Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol (1992) 0.91
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg (2001) 0.89
Liver Transplantation: East versus West. J Clin Exp Hepatol (2013) 0.89
Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin Exp Nephrol (2011) 0.88
The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro. J Virol (2000) 0.87
Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut (1992) 0.87
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int (2011) 0.87
Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci (2007) 0.86
Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg (1998) 0.86
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol (2008) 0.85
The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation (1995) 0.84
Recent advances in hepatic transplantation at the University of Pittsburgh. Clin Transpl (1993) 0.83
Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci (2005) 0.81
Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob (2006) 0.81
Liver transplantation for viral hepatitis in 2015. World J Gastroenterol (2016) 0.80
Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg (1998) 0.80
The Future of Xenotransplantation. Ann Surg (1992) 0.80
Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. J Gen Virol (2009) 0.80
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol (2010) 0.80
Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol (2010) 0.80
Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg (1997) 0.80
Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. Gastroenterol Hepatol (N Y) (2014) 0.79
Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res (2014) 0.79
Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature. Hepat Mon (2013) 0.79
Initiation of liver transplantation in bangladesh: report on the first two successful cases. J Health Popul Nutr (2014) 0.79
Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78
Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2009) 0.78
Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One (2012) 0.78
Interferon alfa-2b therapy in children with chronic hepatitis B. Gut (1993) 0.78
Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. Transplant Proc (1991) 0.77
Multicenter studies of Lamivudine for the treatment and prevention of hepatitis B after liver transplantation. Ochsner J (1999) 0.77
Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol (2015) 0.77
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol (2013) 0.77
Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J Gastroenterol (2006) 0.76
Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol (2015) 0.76
Management of chronic hepatitis B before and after liver transplantation. World J Hepatol (2015) 0.76
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci (2015) 0.76
Hepatitis B virus infection and liver transplantation. Gut (1997) 0.76
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2015) 0.76
Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. World J Gastroenterol (2015) 0.76
Controversies in patient selection for liver transplantation. West J Med (1993) 0.75
Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol (2015) 0.75
Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol (2016) 0.75
The changing face of liver transplantation. Gut (1993) 0.75
Hepatitis B virus infection in liver transplant candidates and recipients. MedGenMed (2005) 0.75
Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol (2016) 0.75
Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience. Int J Clin Exp Pathol (2014) 0.75
Update in liver transplantation. Can Fam Physician (1999) 0.75
Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A non-B hepatitis. Gut (1995) 0.75
The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. J Gastroenterol (2016) 0.75
What is the Risk of Graft Reinfection in Case of Liver Transplantation for Patients With Acute HEV or HAV Infection? J Clin Exp Hepatol (2016) 0.75
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem (1981) 38.93
The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem (1970) 20.22
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: with particular reference to the Australia antigen. Ann Surg (1971) 2.14
Liver allograft. Its use in chronic active hepatitis with macronodular cirrhosis, hepatitis B surface antigen. Arch Surg (1979) 1.80
Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology (1988) 1.74
Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol (1986) 1.63
Liver transplantation: an unfinished product. Transplant Proc (1989) 1.61
Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. Br Med J (1978) 1.46
Human X (mouse X human) hybridomas stably producing human antibodies. Hybridoma (1983) 1.24
Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation (1991) 1.22
Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet (1987) 1.20
Liver transplantation in hepatitis delta virus disease. Lancet (1987) 1.02
Alpha interferon therapy in patients with hepatitis infection undergoing organ transplantation. Transplant Proc (1989) 0.91
Evolution of liver transplantation. Hepatology (1982) 19.54
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Liver transplantation (1). N Engl J Med (1989) 4.53
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Liver from bone marrow in humans. Hepatology (2000) 4.10
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Changes in blood coagulation. Arch Surg (1966) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16